Data from the obutinib combined with RCHOP treatment with primary extranodal initial treatment non-GCB subtype DLBCL were selected for the 2022 ESMO Oral Report

From September 9 to 13, 2022, the 2022 European Society of Oncology (ESMO) Annual Conference will be held

Selected Study: Osbutinib plus RCHOP in patients with extranodal non-proliferative center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with primary extranodal treatment

Orelabrutinib Plus RCHOP for Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Extranodal Disease

Presentation format: Short oral presentation

Abstract code: 627MO

Report Author: Wang Mingyue (Affiliated Cancer Hospital of Guangxi Medical University)

Corresponding Author: Cen Hong (Affiliated Cancer Hospital of Guangxi Medical University)

Reporting time: 12 September, 15:15 - 15:20 (CST)

At present, Nuocheng Jianhua has a deep layout

A registration study of the first-line treatment of oboutinib with DLBCL MCD subtypes has been initiated

2022 The American Society of Clinical Oncology (ASCO) publishes a real-world study of oboutinib for the treatment of DLBCL, and for patients with the MCD subtype of DLBCL, the olibutinib combination therapy regimen has shown encouraging efficacy and good tolerability

From first-line to second-line and above treatment of DLBCL, the company has a combination of multiple drugs including osbutinib, tafasitamab, ICP-B02, and ICP-490 to provide more and better treatment options

About obertinib

Olibutinib is a class 1 new drug developed by Noble Jianhua, which is a highly selective new BTK inhibitor designed to be used in the treatment of lymphoma and autoimmune diseases
.

Obutinib was conditionally approved in China on 25 December 2020 for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and relapsed/refractory sleeve lymphoma (MCL).

At the end of 2021, olibutinib was included in national health insurance to benefit more lymphoma patients
.

In addition, multicenter, multi-indication clinical trials
with olibutinib as a stand-alone or combination are being conducted in China and the United States.

Opoutinib also conducts clinical trials
in China for the treatment of marginal lymphoma (MZL), central nervous system lymphoma (CNSL), fahrenhet macroglobulinemia (WM), and diffuse large B-cell lymphoma (DLBCL).

Obutinib was awarded Breakthrough Therapy Designation by the U.
S.
Food and Drug Administration (FDA) for the treatment of relapsed/refractory studdle lymphoma (R/R MCL
).

A global Phase II clinical study of osbutinib for multiple sclerosis (MS) and a clinical trial in China for the treatment of systemic lupus erythematosus (SLE), primary immune thrombocytopenia (ITP) and neuromyelitis optic disease (NMOSD) are being evaluated
.